Has Sarah Hurd, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,159 in general payments to Sarah Hurd, MD across 616 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sarah Hurd, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sarah Hurd, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sarah Hurd, MD

Family Medicine · Papillion, NENPI 1932140134

Payments from drug & device makers

$9,159in general payments, 2019–2025

Across 616 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Amgen$876
Novo Nordisk$810
Pfizer$697
AstraZeneca$619
Lilly USA, LLC$426
plus $4K from 43 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	139	$1,917
Amgen	65	$876
Novo Nordisk	59	$810
Pfizer	53	$697
AstraZeneca	33	$619
Lilly USA, LLC	27	$426
Johnson & Johnson	23	$369
GSK	31	$352
Bayer	19	$289
Novartis	15	$258
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	12	$206
Aimmune Therapeutics, Inc.	2	$178
Biohaven Pharmaceuticals, Inc.	11	$165
Boehringer Ingelheim	10	$154
Otsuka America Pharmaceutical, Inc.	9	$149
Astellas Pharma US Inc	9	$129
Sanofi-aventis U.S. LLC	8	$120
Kowa Pharmaceuticals America, Inc.	9	$120
Abbott	6	$110
Amarin Pharma, Inc.	7	$106
Lundbeck LLC	5	$73
Biohaven Pharmaceutical Holding Company Ltd.	4	$73
Nestle Healthcare Nutrition Inc.	4	$72
Merck	5	$72
Sumitomo Pharma America, Inc.	4	$67
Arbor Pharmaceuticals, Inc.	5	$66
Boston Scientific	3	$66
Axsome Therapeutics, Inc.	3	$63
E.r. Squibb & Sons, L.L.C.	4	$57
Idorsia Pharmaceuticals US Inc	4	$54
Ironwood Pharmaceuticals, Inc	3	$50
Takeda Pharmaceuticals U.S.A., Inc.	2	$36
Mylan Specialty L.p.	2	$36
Almatica Pharma LLC	2	$30
Biogen	2	$29
Genentech USA, Inc.	2	$28
Xeris Pharmaceuticals, Inc.	2	$27
Scilex Pharmaceuticals Inc.	1	$25
Phathom Pharmaceuticals, Inc.	2	$24
Lexicon Pharmaceuticals, Inc.	1	$22
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$18
Inspire Medical Systems, Inc.	1	$17
Antares Pharma, Inc.	1	$17
Actelion Pharmaceuticals US, Inc.	1	$16
Esperion Therapeutics, Inc.	1	$16
Jazz Pharmaceuticals Inc.	1	$15
Eisai Inc.	1	$14
Acadia Pharmaceuticals Inc	1	$13
Radius Health, Inc.	1	$12

How this compares

$9,159 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024

$88,804

Medicare patients

329

Services billed

6,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Papillion

Lorrie McGillPapillion$1.5M
Jeffry StrohmyerPapillion$9K
Brandon EssinkCreighton$92.8M
Adam BroszGrand Island$60M
David EnszSouth Sioux City$33.3M
Allen HuntLincoln$17.2M
Thomas WolfFremont$8.2M
William FitzgibbonsElkhorn$7M
Kenneth BladOmaha$1.6M
Ralph HaukeOmaha$657K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →